AGWCA
RPRX icon

Annis Gardner Whiting Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-923
Closed -$33.3K – 1393
2025
Q2 		$33.3K Buy
+923
New +$30.6K 0.01% 477

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's RPRX Position: Q3 2025 in Review

Annis Gardner Whiting Capital Advisors sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 923 shares — an estimated $33.3K sold.

Annis Gardner Whiting Capital Advisors first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $33.3K in Q2 2025. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Annis Gardner Whiting Capital Advisors reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 923 Royalty Pharma shares in Q3 2025, an estimated $33.3K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's Royalty Pharma position peaked at $33.3K in Q2 2025.
  • 488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.